logo-loader
viewPolarean Imaging PLC

Polarean Imaging PLC - New System Delivery and Installation

RNS Number : 9061X
Polarean Imaging PLC
24 December 2019
 

Polarean Imaging Plc 

("Polarean" or the "Company")

 

New System Delivery and Installation

 

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces that the Company has delivered and installed its latest research unit order for a 9820 Xenon Polariser system from the University of Iowa Hospitals and Clinics ("UI Hospitals & Clinics").

 

The University of Iowa Hospitals and Clinics is Iowa's only comprehensive academic medical centre; an 811-bed hospital that annually admits about 37,000 patients for in-patient hospital care. For more information: https://uihc.org/basic-facts

 

The total number of the Company's polarisers that are either installed or on order remains 25.

 

Richard Hullihen, CEO of Polarean, said: "I am delighted that we have delivered and installed another polariser, to be used by pulmonology researchers at this well-regarded teaching hospital. The University of Iowa has a long history in medical imaging research and we are excited at the prospect of beginning a new chapter in hyperpolarized xenon cardiopulmonary imaging with them."

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

Polarean Imaging plc

www.polarean.com / www.polarean-ir.com

Richard Hullihen, Chief Executive Officer

Via Walbrook PR

Richard Morgan, Chairman


 


SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

David Hignell, Soltan Tagiev (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)




Walbrook PR

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus / Anna Dunphy

 

Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001

 

 

About Polarean (www.polarean.com)

 

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution medical imaging market.

 

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

 

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate and less harmful to the patient than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

 

The Group also develops and manufactures high performance MRI radiofrequency (RF) coils which are a required component for imaging 129Xe in the MRI system. The development of these coils by the Group facilitates the adoption of the Xenon technology by providing application-specific RF coils which optimise the imaging of 129Xe in MRI equipment for use as a medical diagnostic as well as a method of monitoring the efficacy of therapeutic intervention.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCDDBDDBUDBGCX

Quick facts: Polarean Imaging PLC

Price: 26.5

Market: AIM
Market Cap: £30.33 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Polarean Imaging achieves positive phase III results in two...

Polarean Imaging PLC (LON:POLX) CEO Richard Hullihen tells Proactive its two phase III clinical trials have 'demonstrated handily' that its technology allows doctors and surgeons to visualize aspects of lung function that have gone undetected using traditional magnetic resonances imaging (MRI)...

3 weeks, 5 days ago